Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06880562 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The RESPLASH Study

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jun 2027 → Dec 2027
See other at-risk trials from Tulane University

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 2026 to Dec 2026
    • Primary and study completion pushed from Jun 2027 to Dec 2027
    • Eligibility criteria expanded, about 15 words
  2. Start date: Jan 2026 to Jun 2026
    • Primary and study completion dates: Jan 2027 to Jun 2027
    v6
  3. Eligibility criteria shortened, about 6 wordsv5
  4. Start date: Aug 2025 to Jan 2026
    • Primary and study completion dates: Aug 2026 to Jan 2027
    v4
  5. Start date: Apr 2025 to Aug 2025
    • Primary and study completion dates: Apr 2026 to Aug 2026
    v3
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tulane University
47 trials monitored
See 8 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Hypertension
1,925 trials monitored
See 99 trials at risk
To assess the safety and effectiveness of renal artery denervation with subsequent splanchnic nerves denervation via catheter-based radiofrequency ablation in improving blood pressure and glycemic control in patients with resistant hypertension and type 2 diabetes.
Trial Details
NCT Number NCT06880562
Lead Sponsor Tulane University
Conditions
(from sponsor)		 Resistant Hypertension
Related terms Diabetes Mellitus, Hypertension
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov